
AstraZeneca 79% effective in preventing symptomatic COVID-19, company says
Fox News
AstraZeneca said in a statement early Monday the Phase III trial of its COVID-19 vaccine –which was conducted in the U.S.—showed a 79% effectiveness in preventing symptomatic infections and a 100% efficacy “at preventing severe disease and hospitalization.”
The statement said that the vaccine "was well tolerated" and an independent Data Safety Monitoring Board "identified no safety concerns related to the vaccine." Earlier this month, some European countries suspended the use of the vaccine due to fears that it could increase the risk of blood clots in the recipient. Reuters reported that these countries have resumed the use of the vaccine and health officials have worked to assure the public of its safety.More Related News